| ²é¿´: 1279 | »Ø¸´: 5 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
polarmouseÌú³æ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÇóÁ½¶Î·Ò룬·Ç³£½ô¼±£¬¸Ð¼¤ÌéÁã
|
|
|
In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A. Blood samples were taken over 72 h of each treatmentperiod. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£ Co-administration of A withB, C or D had no effect on A maximum plasma concentration (Cmax) or area under the plasma concentration-time curve (AUC). Similarly, A did not affect the Cmax or AUC for the co-administered drug, except for slight extensions of the 90% CI for the ratio of geometric means for B AUC (upper limit 1.29) andC Cmax (lower limit 0.75). All monotherapies and combination therapies were well tolerated. A can be co-administered with B¡¢C¡¢Dwithout dose adjustment of either drug |
» ²ÂÄãϲ»¶
310Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
290Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
µçÆø×¨Ë¶320Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ289 085602
ÒѾÓÐ33È˻ظ´
Ò»Ö¾Ô¸¹þ¹¤´ó 085600 277 12²Ä¿Æ»ùÇóµ÷¼Á
ÒѾÓÐ24È˻ظ´
268·Ö085602»¯Ñ§¹¤³Ìµ÷¼Á
ÒѾÓÐ28È˻ظ´
»¯Ñ§¹¤³Ìµ÷¼Á289
ÒѾÓÐ50È˻ظ´
Çóµ÷¼Á£¬262»úеר˶
ÒѾÓÐ8È˻ظ´
305Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
327Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
polarmouse
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 25.8
- Ìû×Ó: 24
- ÔÚÏß: 4.1Сʱ
- ³æºÅ: 924818
- ×¢²á: 2009-12-10
- רҵ: Éñ¾ÏµÍ³ºÍ¾«Éñ¼²²¡ÆäËû¿Æ
2Â¥2011-05-08 11:43:15
polarmouse
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 25.8
- Ìû×Ó: 24
- ÔÚÏß: 4.1Сʱ
- ³æºÅ: 924818
- ×¢²á: 2009-12-10
- רҵ: Éñ¾ÏµÍ³ºÍ¾«Éñ¼²²¡ÆäËû¿Æ
3Â¥2011-05-08 11:43:29
polarmouse
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 25.8
- Ìû×Ó: 24
- ÔÚÏß: 4.1Сʱ
- ³æºÅ: 924818
- ×¢²á: 2009-12-10
- רҵ: Éñ¾ÏµÍ³ºÍ¾«Éñ¼²²¡ÆäËû¿Æ
4Â¥2011-05-08 11:43:49
Mally89
Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)
T_T
- ·ÒëEPI: 79
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ¹ó±ö: 1.257
- ½ð±Ò: 5347.3
- É¢½ð: 8936
- ºì»¨: 49
- Ìû×Ó: 3712
- ÔÚÏß: 1225.5Сʱ
- ³æºÅ: 1150928
- ×¢²á: 2010-11-19
- ÐÔ±ð: MM
- רҵ: Ö×ÁöÃâÒß
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
sltmac(½ð±Ò+41, ·ÒëEPI+1): 2011-05-16 07:52:15
sltmac: ¼ÌÐøÅ¬Á¦~~ 2011-05-16 07:52:30
sltmac(½ð±Ò+41, ·ÒëEPI+1): 2011-05-16 07:52:15
sltmac: ¼ÌÐøÅ¬Á¦~~ 2011-05-16 07:52:30
|
In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A¡£ ÔÚ½øÐгÖÐøÈý¸öÖÜÆÚ£¬Ëæ»ú¿ª·Å±ê¼ÇµÄÈý¸ö´¦Àí½»²æÖÎÁÆÑо¿µ±ÖУ¬10¸öÑù±¾ÖмÓÈë10mgµÄA£¬45mgµÄB»òÕß¶þÕߵĻìºÏÎÁíÍâ20¸öÑù±¾ÖмÓÈë20mgµÄA¡¢1000mgµÄC»òÕß¶þÕߵĻìºÏÎï¡£ÔÚÁíÒ»¸öËæ»ú¿ª·Å±ê¼Ç£¬Î¬³Ö5¸öÖÜÆÚµÄ5¸ö½»²æ²»Æ½ºâ´¦ÀíÑо¿µ±ÖУ¬Ê×ÏÈÏò12¸öÑù±¾ÖмÓÈë20mg A£¬4mg D»òÕß¶þÕß»ìºÏÎȻºóÔÙ¼ÓÈë100mgÎ÷ËûÁÐÍ¡»ò¼ÓÓÐ20mgAµÄÎ÷ËûÁÐÍ¡¡£ |
5Â¥2011-05-08 15:22:48
Mally89
Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)
T_T
- ·ÒëEPI: 79
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ¹ó±ö: 1.257
- ½ð±Ò: 5347.3
- É¢½ð: 8936
- ºì»¨: 49
- Ìû×Ó: 3712
- ÔÚÏß: 1225.5Сʱ
- ³æºÅ: 1150928
- ×¢²á: 2010-11-19
- ÐÔ±ð: MM
- רҵ: Ö×ÁöÃâÒß
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
Blood samples were taken over 72 h of each treatment period. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£ ÿ¸ö´¦ÀíÖÜÆÚ72Сʱ֮ºó½«ÑªÒºÑù±¾È¡³ö¡£¸ù¾Ý¼¸ºÎ·½·¨ºÍ»ìºÏÎï90%ÖÃÐÅÇø¼ä£¨ÔÚ0.8-1.25·¶Î§Äڵĵ¥Ò»ÖÎÁÆ£©µÄ±ÈÖµÀ´Åж¨½»²æ·´Ó¦ÖÐÊÇ·ñȱ·¦PK¡£ |
6Â¥2011-05-08 16:09:08













»Ø¸´´ËÂ¥